# Pan-cancer plasma DNA methylation PCR test (Wuhan Ammunition Life-tech)

Source: https://onco.cc/trials/wuhan-pan-cancer-methylation-pcr/  
OnCo record `wuhan-pan-cancer-methylation-pcr` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese study developing a low-cost DNA methylation blood test for several cancers that runs on ordinary PCR machines.

## Summary

Pan-cancer plasma DNA methylation PCR test (NCT05685524) is an observational study sponsored by Wuhan Ammunition Life-tech Co., Ltd. It aims to identify plasma methylation markers for multi-cancer detection read by multiplex fluorescence PCR.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 17 January 2023), with an estimated 3,000 participants, a start on 1 July 2022 and primary completion expected in August 2023.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Registry id: NCT05685524
- Phase: observational
- Setting: People with and without cancer in China, developing a multiplex fluorescence PCR methylation test
- Sponsor: Wuhan Ammunition Life-tech Co., Ltd
- Enrolled: 3000

## Sources

- ClinicalTrials.gov NCT05685524: https://clinicaltrials.gov/study/NCT05685524

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/wuhan-pan-cancer-methylation-pcr.json